1. Volume 65, Issue 4, Pages 674-682 (October 2016)
Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study 
Jian Sun, Hong Ma, Qing Xie, Yao Xie, Yongtao Sun, Hao Wang, Guangfeng Shi, Mobin Wan, Junqi Niu, Qin Ning, Yanyan Yu, Huijuan Zhou, Jun Cheng, Wenzhen Kang, Yi Xie, Rong Fan, Lai Wei, Hui Zhuang, Jidong Jia, Jinlin Hou 
Journal of Hepatology 
Volume 65, Issue 4, Pages (October 2016)
DOI: /j.jhep
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

2. Journal of Hepatology 2016 65, 674-682DOI: (10. 1016/j. jhep. 2016. 05
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

3. Fig. 1
Schematic representation of the study design. PegIFN, pegylated interferon; ADV, adefovir.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

4. Fig. 2 Subject disposition of the study. AE, adverse events.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

5. Fig. 3
Mean decline of HBsAg (A) and HBV DNA (B) from baseline to 24weeks post-treatment. p value was calculated from a Student’s t test between early responder and non-early responder. Last observation carried forward procedure was used to impute the missing data pertaining to the treatment period. EOT, end of treatment; EOF, end of follow-up.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

6. Fig. 4
Rates of response at end of follow-up according to HBsAg and/or HBV DNA at week 24.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions